United States· US:55135-132_18d71575-4896-4cfe-a9e8-a90fbd8bdb8a
TRODELVY
A sacituzumab govitecan product containing sacituzumab govitecan, registered in United States by Gilead Sciences, Inc.. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Sacituzumab govitecan is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FX17 (sacituzumab govitecan), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Sacituzumab govitecan · ATC L01FX17
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of sacituzumab govitecan costs, country by country.
Normalised to the WHO defined daily dose (67 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Sacituzumab govitecan · price per daily dose (67 mg)
USD · FX 28 Sept 2026
- CH Switzerland$458.52
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- SACITUZUMAB GOVITECAN
- Manufacturer
- Gilead Sciences, Inc.
- Country
- United States (US)
- ATC code
- L01FX17
- ATC class
- Sacituzumab govitecan
- Defined daily dose
- 67 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc1155135132011 VIAL in 1 BOX (55135-132-01) / 1 POWDER, FOR SOLUTION in 1 VIAL
Regulatory notes
Interactions
60 interactions on record for sacituzumab govitecan.
Graded by severity as the source publishes them — 36 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sacituzumab govitecan · interactions on record
60 records
- 36 severe
- 24 moderate
Most severe, free to view
- FostamatinibB02BX09severe
- CladribineL01BB04severe
- IrinotecanL01CE02severe
- NilotinibL01EA03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Sacituzumab govitecan in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaTRODELVYGILEAD SCIENCES CANADA INC
- FinlandTrodelvyOrifarm Oy
- SpainTRODELVY 200 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONGilead Sciences Ireland Unlimited Company
- CzechiaTRODELVYGilead Sciences Ireland UC, Carrigtohill
- FranceTRODELVY 200 mg, poudre pour solution à diluer pour perfusionGILEAD SCIENCES IRELAND UC (IRLANDE)
- United KingdomTrodelvy 180mg powder for concentrate for solution for infusion vialsGilead Sciences Ltd
- BelgiumTrodelvy 200 mgGilead Sciences Ireland UC
- IcelandTrodelvyGilead Sciences Ireland UC*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Trodelvy
- Liechtenstein · Trodelvy
- Norway · Trodelvy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6288ca0e-6ef5-4261-9c92-df402b6788e5 GET /v1/drugs/6288ca0e-6ef5-4261-9c92-df402b6788e5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unii": {
"unii": "M9BYU8XDQ6",
"rxcui": "2360232",
"inchikey": null,
"display_name": "SACITUZUMAB GOVITECAN",
"substance_type": "protein",
"ingredient_type": "INGREDIENT SUBSTANCE"
},
"route": "INTRAVENOUS",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 5
},
"spl_meta": {
"57a597d2-03f0-472e-b148-016d7169169d": {
"match": "brand_token",
"title": "TRODELVY (SACITUZUMAB GOVITECAN) POWDER, FOR SOLUTION [GILEAD SCIENCES, INC.]",
"spl_version": "18",
"published_date": "2025-12-16"
}
},
"productid": "55135-132_18d71575-4896-4cfe-a9e8-a90fbd8bdb8a",
"productndc": "55135-132",
"dosage_form": "POWDER, FOR SOLUTION",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "SACITUZUMAB GOVITECAN",
"proprietary_name": "TRODELVY",
"active_ingred_unit": "mg/1",
"application_number": "BLA761115",
"marketing_category": "BLA",
"nonproprietary_name": "SACITUZUMAB GOVITECAN",
"start_marketing_date": "20200422",
"active_numerator_strength": "180"
}See everything about sacituzumab govitecan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.